Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 13
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer.
Lee MS, Dennis C, Naqvi I, Dailey L, Lorzadeh A, Ye G, Zaytouni T, Adler A, Hitchcock DS, Lin L, Hoffman MT, Bhuiyan AM, Barth JL, Machacek ME, Mino-Kenudson M, Dougan SK, Jadhav U, Clish CB, Kalaany NY. Lee MS, et al. Nature. 2023 Apr;616(7956):339-347. doi: 10.1038/s41586-023-05891-2. Epub 2023 Mar 29. Nature. 2023. PMID: 36991126 Free PMC article.
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.
Qiang L, Hoffman MT, Ali LR, Castillo JI, Kageler L, Temesgen A, Lenehan P, Wang SJ, Bello E, Cardot-Ruffino V, Uribe GA, Yang A, Dougan M, Aguirre AJ, Raghavan S, Pelletier M, Cremasco V, Dougan SK. Qiang L, et al. Gastroenterology. 2023 Oct;165(4):874-890.e10. doi: 10.1053/j.gastro.2023.05.038. Epub 2023 May 30. Gastroenterology. 2023. PMID: 37263309 Free PMC article.
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, Feng H, Geisberg J, Wang J, Evans KE, Lyu H, Schalck A, Feng N, Lopez AM, Bristow CA, Kim MP, Rajapakshe KI, Bahrambeigi V, Roth JA, Garg K, Guerrero PA, Stanger BZ, Cristea S, Lowe SW, Baslan T, Van Allen EM, Mancias JD, Chan E, Anderson A, Katlinskaya YV, Shalek AK, Hong DS, Pant S, Hallin J, Anderes K, Olson P, Heffernan TP, Chugh S, Christensen JG, Maitra A, Wolpin BM, Raghavan S, Nowak JA, Winter PS, Dougan SK, Aguirre AJ. Dilly J, et al. Cancer Discov. 2024 Nov 1;14(11):2135-2161. doi: 10.1158/2159-8290.CD-24-0177. Cancer Discov. 2024. PMID: 38975874 Free PMC article.
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.
Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, McCreary J, Boschert T, Wang ES, Suo S, Marangoni F, Mempel TR, Long HW, Wucherpfennig KW, Dougan M, Gray NS, Yuan GC, Goel S, Tolaney SM, Dougan SK. Heckler M, et al. Cancer Discov. 2021 Oct;11(10):2564-2581. doi: 10.1158/2159-8290.CD-20-1540. Epub 2021 May 3. Cancer Discov. 2021. PMID: 33941591 Free PMC article.
Metabolic modulation of mitochondrial mass during CD4+ T cell activation.
Kurmi K, Liang D, van de Ven R, Georgiev P, Gassaway BM, Han S, Notarangelo G, Harris IS, Yao CH, Park JS, Hu SH, Peng J, Drijvers JM, Boswell S, Sokolov A, Dougan SK, Sorger PK, Gygi SP, Sharpe AH, Haigis MC. Kurmi K, et al. Cell Chem Biol. 2023 Sep 21;30(9):1064-1075.e8. doi: 10.1016/j.chembiol.2023.08.008. Cell Chem Biol. 2023. PMID: 37716347 Free PMC article.
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, Bekaii-Saab TS, Elias R, Merchant N, Dias Costa A, Lenehan P, Cardot-Ruffino V, Rodig S, Pfaff K, Dougan SK, Nowak JA, Varadhachary GR, Slingluff CL, Rahma O. Katz MHG, et al. J Immunother Cancer. 2023 Dec 1;11(12):e007586. doi: 10.1136/jitc-2023-007586. J Immunother Cancer. 2023. PMID: 38040420 Free PMC article. Clinical Trial.
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy.
Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J, Chun JH, Wang W, Lajoie MJ, Ravichandran R, Kuo YH, Dougan SK, Riddell SR, Spangler JB, Dougan M, Silva DA, Baker D. Quijano-Rubio A, et al. Nat Biotechnol. 2023 Apr;41(4):532-540. doi: 10.1038/s41587-022-01510-z. Epub 2022 Oct 31. Nat Biotechnol. 2023. PMID: 36316485 Free PMC article.
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Cardot-Ruffino V, Bollenrucher N, Delius L, Wang SJ, Brais LK, Remland J, Keheler CE, Sullivan KM, Abrams TA, Biller LH, Enzinger PC, McCleary NJ, Patel AK, Rubinson DA, Schlechter B, Slater S, Yurgelun MB, Cleary JM, Perez K, Dougan M, Ng K, Wolpin BM, Singh H, Dougan SK. Cardot-Ruffino V, et al. J Immunother Cancer. 2023 Jun;11(6):e006589. doi: 10.1136/jitc-2022-006589. J Immunother Cancer. 2023. PMID: 37344102 Free PMC article.
20 results